TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases

TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting by revealing additional data from its Phase ... Read More